No Data
No Data
Allogene Therapeutics Announces Patient Screening Underway For Pivotal Phase 2 ALPHA3 Trial At Rocky Mountain Cancer Centers, Astera Cancer Care, And Norton Cancer Institute; ALPHA3 To Offer CAR T As First Line Treatment At Community Cancer Centers,...
Allogene Therapeutics Announces Patient Screening Underway For Pivotal Phase 2 ALPHA3 Trial At Rocky Mountain Cancer Centers, Astera Cancer Care, And Norton Cancer Institute; ALPHA3 To Offer CAR T As
Express News | Allogene Therapeutics : Alpha3 Expected to Complete Enrollment in 1H 2026; Potential Bla Submission in 2027
Express News | Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 Alpha3 Trial Evaluating Cemacabtagene Ansegedleucel (Cema-Cel) as First Line (1L) Consolidation Treatment for Patients With Large B-Cell Lymphoma (Lbcl)
William Blair Maintains Allogene Therapeutics(ALLO.US) With Buy Rating
William Blair analyst Sami Corwin maintains $Allogene Therapeutics(ALLO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.4% and a total average return of -4.4% o
Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock?
Allogene Therapeutics(ALLO.US) Director Sells US$42,488.43 in Common Stock
$Allogene Therapeutics(ALLO.US)$ Director MESSEMER DEBORAH M. sold 18,641 shares of common stock on Jun 18, 2024 at an average price of $2.2793 for a total value of $42,488.43.Source: Announcement Wha
No Data